These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 12714650

  • 21. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
    Wade RL, Chaudhari P, Natoli JL, Taylor RJ, Nathanson BH, Horn DL.
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole.
    Carrillo-Muñoz AJ, Quindós G, Tur C, Ruesga M, Alonso R, del Valle O, Rodriguez V, Arévalo MP, Salgado J, Martin-Mazuelos E, Bornay-Llinares FJ, del Palacio A, Cuétara M, Gasser I, Hernández-Molina JM, Pemán J.
    Chemotherapy; 2000 Jul; 46(4):235-44. PubMed ID: 10859429
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Amphotericin B formulations: a comparative review of efficacy and toxicity.
    Hamill RJ.
    Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies.
    Adedoyin A, Bernardo JF, Swenson CE, Bolsack LE, Horwith G, DeWit S, Kelly E, Klasterksy J, Sculier JP, DeValeriola D, Anaissie E, Lopez-Berestein G, Llanos-Cuentas A, Boyle A, Branch RA.
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2201-8. PubMed ID: 9333048
    [Abstract] [Full Text] [Related]

  • 30. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B.
    Denning DW, Warn P.
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2592-9. PubMed ID: 10543734
    [Abstract] [Full Text] [Related]

  • 31. Toxicities and pharmacokinetics of subconjunctival injection of liposomal amphotericin B.
    Kaji Y, Yamamoto E, Hiraoka T, Oshika T.
    Graefes Arch Clin Exp Ophthalmol; 2009 Apr; 247(4):549-53. PubMed ID: 19043733
    [Abstract] [Full Text] [Related]

  • 32. What is the current and future status of conventional amphotericin B?
    Kleinberg M.
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
    [Abstract] [Full Text] [Related]

  • 33. [A pharmacodynamics study of an intravitreal amphotericin B drug delivery system for the treatment of experimental Aspergillus fumigatus endophthalmitis].
    Yang X, Dong XG, Liu AM, Sun SY, Xie LX, Wang SG.
    Zhonghua Yan Ke Za Zhi; 2007 Jun; 43(6):546-53. PubMed ID: 17897534
    [Abstract] [Full Text] [Related]

  • 34. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis.
    Lewis RE, Albert ND, Liao G, Hou J, Prince RA, Kontoyiannis DP.
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1298-304. PubMed ID: 20038620
    [Abstract] [Full Text] [Related]

  • 35. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study.
    Falci DR, da Rosa FB, Pasqualotto AC.
    Mycoses; 2015 Feb; 58(2):104-12. PubMed ID: 25590436
    [Abstract] [Full Text] [Related]

  • 36. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS.
    Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, Mildvan D, Fan-Havard P, Eng RH, Patterson TF, Pottage JC, Simberkoff MS, Wolf J, Meyer RD, Gupta R, Lee LW, Gordon DS.
    Clin Infect Dis; 1996 Feb; 22(2):315-21. PubMed ID: 8838189
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
    Cannon JP, Garey KW, Danziger LH.
    Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
    [Abstract] [Full Text] [Related]

  • 39. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
    Hachem RY, Boktour MR, Hanna HA, Husni RN, Torres HA, Afif C, Kontoyiannis DP, Raad II.
    Cancer; 2008 Mar 15; 112(6):1282-7. PubMed ID: 18224662
    [Abstract] [Full Text] [Related]

  • 40. Acrocyanosis developed with amphotericin B deoxycholate but not with amphotericin B lipid complex.
    Ozaras R, Yemisen M, Mete B, Mert A, Ozturk R, Tabak F.
    Mycoses; 2007 May 15; 50(3):242. PubMed ID: 17472626
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.